Can the Future be Bright with Advances in Diabetic Eye Care?

Samantha Paul; Christian Kim; Mohamed Kamel Soliman; Warren Sobol; Jose J Echegaray; Shree Kurup

doi:10.1016/j.ecl.2022.06.004

Can the Future be Bright with Advances in Diabetic Eye Care?

Endocrinol Metab Clin North Am. 2023 Mar;52(1):89-99. doi: 10.1016/j.ecl.2022.06.004. Epub 2022 Nov 18.

Authors

Samantha Paul¹, Christian Kim¹, Mohamed Kamel Soliman², Warren Sobol³, Jose J Echegaray³, Shree Kurup⁴

Affiliations

¹ University Hospitals Eye Institute/Department of Ophthalmology and Visual Sciences, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
² Department of Ophthalmology, Assiut University Hospitals, Al Walideyah Al Qebleyah, Asyut 2, Assiut Governorate 2074020, Egypt; Case Western Reserve University, Vitreoretinal Diseases & Surgery, Ocular Immunology & Uveitis, Department of Ophthalmology, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
³ University Hospitals Eye Institute/Department of Ophthalmology and Visual Sciences, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA; Case Western Reserve University, Vitreoretinal Diseases & Surgery, Ocular Immunology & Uveitis, Department of Ophthalmology, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
⁴ University Hospitals Eye Institute/Department of Ophthalmology and Visual Sciences, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA; Case Western Reserve University, Vitreoretinal Diseases & Surgery, Ocular Immunology & Uveitis, Department of Ophthalmology, University Hospitals, 11100 Euclid Avenue, Cleveland, OH 44106, USA. Electronic address: Shree.Kurup@UHhospitals.org.

PMID: 36754499
DOI: 10.1016/j.ecl.2022.06.004

Abstract

The prevalence of diabetic retinopathy is steadily increasing as the population of patients with diabetes grows. In the past decade, the development of anti-VEGF agents has dramatically changed the treatment landscape for diabetic retinopathy and diabetic macular edema (DME). Newer agents in development aim to reduce the treatment burden of diabetic retinopathy.

Keywords: Diabetic; Diabetic macular edema; Ophthalmic imaging; Retinopathy.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Diabetes Mellitus*
Diabetic Retinopathy* / drug therapy
Diabetic Retinopathy* / therapy
Humans
Macular Edema* / drug therapy
Macular Edema* / therapy
Prevalence

Substances

Angiogenesis Inhibitors